Cancer drug resistance: The central role of the karyotype☆

2007 ◽  
Vol 10 (1-2) ◽  
pp. 51-58 ◽  
Author(s):  
P DUESBERG ◽  
R LI ◽  
R SACHS ◽  
A FABARIUS ◽  
M UPENDER ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Cancer Drug ◽  
Cancer Drug Resistance

scholarly journals Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives

2012 ◽  
Vol 4 (8) ◽  
pp. 675-684 ◽  
Author(s):  
Nicholas A. Saunders ◽  
Fiona Simpson ◽  
Erik W. Thompson ◽  
Michelle M. Hill ◽  
Liliana Endo‐Munoz ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Cancer Drug ◽  
Cancer Drug Resistance ◽  
Intratumoural Heterogeneity

scholarly journals Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance

2012 ◽  
Vol 83 (8) ◽  
pp. 1084-1103 ◽  
Author(s):  
Karthika Natarajan ◽  
Yi Xie ◽  
Maria R. Baer ◽  
Douglas D. Ross
Keyword(s):  
Breast Cancer ◽  
Drug Resistance ◽  
Breast Cancer Resistance Protein ◽  
Cancer Drug ◽  
Cancer Resistance ◽  
Cancer Drug Resistance ◽  
Resistance Protein

scholarly journals The role of photodynamic therapy in overcoming cancer drug resistance

2015 ◽  
Vol 14 (8) ◽  
pp. 1476-1491 ◽  
Author(s):  
Bryan Q. Spring ◽  
Imran Rizvi ◽  
Nan Xu ◽  
Tayyaba Hasan
Keyword(s):  
Drug Resistance ◽  
Photodynamic Therapy ◽  
Cancer Cells ◽  
Cancer Drug ◽  
Cancer Drug Resistance

This perspective highlights unique mechanisms of photodynamic therapy (PDT) that can be utilized to overcome classical drug resistance and re-sensitize resistant cancer cells for standard therapies.

The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance

2013 ◽  
Vol 67 (7) ◽  
pp. 669-680 ◽  
Author(s):  
Radosław Januchowski ◽  
Karolina Wojtowicz ◽  
Maciej Zabel
Keyword(s):  
Drug Resistance ◽  
Aldehyde Dehydrogenase ◽  
Cancer Drug ◽  
Cancer Drug Resistance

scholarly journals The role of exosomal long non-coding RNAs in cancer drug resistance

2019 ◽  
Author(s):  
Mireia Cruz De los Santos ◽  
Mihnea P. Dragomir ◽  
George A. Calin
Keyword(s):  
Drug Resistance ◽  
Cancer Drug ◽  
Cancer Drug Resistance ◽  
Non Coding Rnas

The role of deubiquitinating enzymes in cancer drug resistance

2020 ◽  
Vol 85 (4) ◽  
pp. 627-639
Author(s):  
Parthasaradhireddy Tanguturi ◽  
Kye-Seong Kim ◽  
Suresh Ramakrishna
Keyword(s):  
Drug Resistance ◽  
Cancer Drug ◽  
Deubiquitinating Enzymes ◽  
Cancer Drug Resistance

scholarly journals The role of galectin-3 in cancer drug resistance

2007 ◽  
Vol 10 (3) ◽  
pp. 101-108 ◽  
Author(s):  
Tomoharu Fukumori ◽  
Hiro-omi Kanayama ◽  
Avraham Raz
Keyword(s):  
Drug Resistance ◽  
Cancer Drug ◽  
Cancer Drug Resistance ◽  
Galectin 3

The Regulatory Role of Long Noncoding RNAs in Cancer Drug Resistance

2016 ◽  
pp. 207-227 ◽  
Author(s):  
Marjan E. Askarian-Amiri ◽  
Euphemia Leung ◽  
Graeme Finlay ◽  
Bruce C. Baguley
Keyword(s):  
Drug Resistance ◽  
Noncoding Rnas ◽  
Long Noncoding Rnas ◽  
Regulatory Role ◽  
Cancer Drug ◽  
Cancer Drug Resistance

scholarly journals The role of epithelial–mesenchymal transition-regulating transcription factors in anti-cancer drug resistance

2021 ◽  
Author(s):  
Jihye Seo ◽  
Jain Ha ◽  
Eunjeong Kang ◽  
Sayeon Cho
Keyword(s):  
Drug Resistance ◽  
Transcription Factors ◽  
Epithelial Mesenchymal Transition ◽  
Cancer Drug ◽  
Preclinical Studies ◽  
Mesenchymal Transition ◽  
Cancer Drug Resistance ◽  
Anti Cancer ◽  
Future Challenges

AbstractThe complex orchestration of gene expression that mediates the transition of epithelial cells into mesenchymal cells is implicated in cancer development and metastasis. As the primary regulator of the process, epithelial-mesenchymal transition-regulating transcription factors (EMT-TFs) play key roles in metastasis. They are also highlighted in recent preclinical studies on resistance to cancer therapy. This review describes the role of three main EMT-TFs, including Snail, Twist1, and zinc-finger E homeobox-binding 1 (ZEB1), relating to drug resistance and current possible approaches for future challenges targeting EMT-TFs.

The role of metabolism and tunneling nanotube-mediated intercellular mitochondria exchange in cancer drug resistance

2018 ◽  
Vol 475 (14) ◽  
pp. 2305-2328 ◽  
Author(s):  
Yalda Hekmatshoar ◽  
Jean Nakhle ◽  
Mireille Galloni ◽  
Marie-Luce Vignais
Keyword(s):  
Drug Resistance ◽  
Cancer Cell ◽  
Metabolic Pathways ◽  
Cancer Drug ◽  
Special Focus ◽  
Cellular Interactions ◽  
Tunneling Nanotubes ◽  
Resistance To Therapy ◽  
Cancer Drug Resistance

Intercellular communications play a major role in tissue homeostasis. In pathologies such as cancer, cellular interactions within the tumor microenvironment (TME) contribute to tumor progression and resistance to therapy. Tunneling nanotubes (TNTs) are newly discovered long-range intercellular connections that allow the exchange between cells of various cargos, ranging from ions to whole organelles such as mitochondria. TNT-transferred mitochondria were shown to change the metabolism and functional properties of recipient cells as reported for both normal and cancer cells. Metabolic plasticity is now considered a hallmark of cancer as it notably plays a pivotal role in drug resistance. The acquisition of cancer drug resistance was also associated to TNT-mediated mitochondria transfer, a finding that relates to the role of mitochondria as a hub for many metabolic pathways. In this review, we first give a brief overview of the various mechanisms of drug resistance and of the cellular communication means at play in the TME, with a special focus on the recently discovered TNTs. We further describe recent studies highlighting the role of the TNT-transferred mitochondria in acquired cancer cell drug resistance. We also present how changes in metabolic pathways, including glycolysis, pentose phosphate and lipid metabolism, are linked to cancer cell resistance to therapy. Finally, we provide examples of novel therapeutic strategies targeting mitochondria and cell metabolism as a way to circumvent cancer cell drug resistance.

Sign in / Sign up

Export Citation Format

Share Document